Logo image of SGRY

SURGERY PARTNERS INC (SGRY) Stock Fundamental Analysis

NASDAQ:SGRY - Nasdaq - US86881A1007 - Common Stock - Currency: USD

22.74  -0.36 (-1.56%)

After market: 22.74 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SGRY. SGRY was compared to 102 industry peers in the Health Care Providers & Services industry. While SGRY is still in line with the averages on profitability rating, there are concerns on its financial health. SGRY has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year SGRY was profitable.
In the past year SGRY had a positive cash flow from operations.
In the past 5 years SGRY always reported negative net income.
In the past 5 years SGRY always reported a positive cash flow from operatings.
SGRY Yearly Net Income VS EBIT VS OCF VS FCFSGRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

SGRY's Return On Assets of -2.43% is in line compared to the rest of the industry. SGRY outperforms 42.16% of its industry peers.
With a Return On Equity value of -11.11%, SGRY is not doing good in the industry: 61.76% of the companies in the same industry are doing better.
SGRY has a Return On Invested Capital (5.07%) which is comparable to the rest of the industry.
SGRY had an Average Return On Invested Capital over the past 3 years of 5.03%. This is below the industry average of 9.62%.
The last Return On Invested Capital (5.07%) for SGRY is above the 3 year average (5.03%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -2.43%
ROE -11.11%
ROIC 5.07%
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
SGRY Yearly ROA, ROE, ROICSGRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

1.3 Margins

SGRY has a better Operating Margin (14.92%) than 86.27% of its industry peers.
In the last couple of years the Operating Margin of SGRY has remained more or less at the same level.
SGRY's Gross Margin of 26.51% is in line compared to the rest of the industry. SGRY outperforms 52.94% of its industry peers.
In the last couple of years the Gross Margin of SGRY has remained more or less at the same level.
Industry RankSector Rank
OM 14.92%
PM (TTM) N/A
GM 26.51%
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
SGRY Yearly Profit, Operating, Gross MarginsSGRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SGRY is destroying value.
SGRY has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SGRY has been increased compared to 5 years ago.
The debt/assets ratio for SGRY is higher compared to a year ago.
SGRY Yearly Shares OutstandingSGRY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
SGRY Yearly Total Debt VS Total AssetsSGRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

SGRY has an Altman-Z score of 0.82. This is a bad value and indicates that SGRY is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.82, SGRY is not doing good in the industry: 71.57% of the companies in the same industry are doing better.
SGRY has a debt to FCF ratio of 20.49. This is a negative value and a sign of low solvency as SGRY would need 20.49 years to pay back of all of its debts.
The Debt to FCF ratio of SGRY (20.49) is worse than 60.78% of its industry peers.
SGRY has a Debt/Equity ratio of 1.98. This is a high value indicating a heavy dependency on external financing.
SGRY has a Debt to Equity ratio of 1.98. This is in the lower half of the industry: SGRY underperforms 73.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.98
Debt/FCF 20.49
Altman-Z 0.82
ROIC/WACC0.61
WACC8.28%
SGRY Yearly LT Debt VS Equity VS FCFSGRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

SGRY has a Current Ratio of 1.89. This is a normal value and indicates that SGRY is financially healthy and should not expect problems in meeting its short term obligations.
SGRY has a better Current ratio (1.89) than 71.57% of its industry peers.
A Quick Ratio of 1.73 indicates that SGRY should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.73, SGRY is doing good in the industry, outperforming 67.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.73
SGRY Yearly Current Assets VS Current LiabilitesSGRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

SGRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.87%.
Looking at the last year, SGRY shows a quite strong growth in Revenue. The Revenue has grown by 13.54% in the last year.
The Revenue has been growing by 11.20% on average over the past years. This is quite good.
EPS 1Y (TTM)-12.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
Revenue 1Y (TTM)13.54%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%8.17%

3.2 Future

The Earnings Per Share is expected to grow by 23.05% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 10.13% on average over the next years. This is quite good.
EPS Next Y0.71%
EPS Next 2Y17.58%
EPS Next 3Y17.13%
EPS Next 5Y23.05%
Revenue Next Year9.65%
Revenue Next 2Y9.53%
Revenue Next 3Y9.67%
Revenue Next 5Y10.13%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SGRY Yearly Revenue VS EstimatesSGRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B 4B 5B
SGRY Yearly EPS VS EstimatesSGRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 1 -1 2 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

SGRY is valuated quite expensively with a Price/Earnings ratio of 25.84.
SGRY's Price/Earnings ratio is a bit cheaper when compared to the industry. SGRY is cheaper than 60.78% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.31, SGRY is valued at the same level.
The Price/Forward Earnings ratio is 17.50, which indicates a rather expensive current valuation of SGRY.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SGRY indicates a somewhat cheap valuation: SGRY is cheaper than 65.69% of the companies listed in the same industry.
SGRY is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.13, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 25.84
Fwd PE 17.5
SGRY Price Earnings VS Forward Price EarningsSGRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

SGRY's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. SGRY is cheaper than 69.61% of the companies in the same industry.
SGRY's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. SGRY is cheaper than 71.57% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.82
EV/EBITDA 9.99
SGRY Per share dataSGRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 -20

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SGRY does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as SGRY's earnings are expected to grow with 17.13% in the coming years.
PEG (NY)36.57
PEG (5Y)N/A
EPS Next 2Y17.58%
EPS Next 3Y17.13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGRY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURGERY PARTNERS INC

NASDAQ:SGRY (6/13/2025, 8:00:02 PM)

After market: 22.74 0 (0%)

22.74

-0.36 (-1.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners71.88%
Inst Owner Change0.04%
Ins Owners1.32%
Ins Owner Change7.9%
Market Cap2.91B
Analysts80
Price Target32.66 (43.62%)
Short Float %12.53%
Short Ratio9.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.69%
Min EPS beat(2)-24.34%
Max EPS beat(2)14.96%
EPS beat(4)2
Avg EPS beat(4)-8.11%
Min EPS beat(4)-26.04%
Max EPS beat(4)14.96%
EPS beat(8)6
Avg EPS beat(8)33.9%
EPS beat(12)8
Avg EPS beat(12)145.55%
EPS beat(16)11
Avg EPS beat(16)116.96%
Revenue beat(2)1
Avg Revenue beat(2)0.12%
Min Revenue beat(2)-2.1%
Max Revenue beat(2)2.34%
Revenue beat(4)2
Avg Revenue beat(4)-0.02%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)2.34%
Revenue beat(8)3
Avg Revenue beat(8)-0.73%
Revenue beat(12)4
Avg Revenue beat(12)-1.04%
Revenue beat(16)6
Avg Revenue beat(16)-0.9%
PT rev (1m)0.73%
PT rev (3m)-2.11%
EPS NQ rev (1m)-26.83%
EPS NQ rev (3m)-24.15%
EPS NY rev (1m)-8.31%
EPS NY rev (3m)-3.35%
Revenue NQ rev (1m)-0.44%
Revenue NQ rev (3m)-2.56%
Revenue NY rev (1m)-0.29%
Revenue NY rev (3m)-0.06%
Valuation
Industry RankSector Rank
PE 25.84
Fwd PE 17.5
P/S 0.92
P/FCF 16.82
P/OCF 10.98
P/B 1.67
P/tB N/A
EV/EBITDA 9.99
EPS(TTM)0.88
EY3.87%
EPS(NY)1.3
Fwd EY5.72%
FCF(TTM)1.35
FCFY5.95%
OCF(TTM)2.07
OCFY9.11%
SpS24.76
BVpS13.58
TBVpS-26.77
PEG (NY)36.57
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.43%
ROE -11.11%
ROCE 6.42%
ROIC 5.07%
ROICexc 5.23%
ROICexgc 18.9%
OM 14.92%
PM (TTM) N/A
GM 26.51%
FCFM 5.46%
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
ROICexc(3y)5.23%
ROICexc(5y)4.72%
ROICexgc(3y)18.5%
ROICexgc(5y)17.9%
ROCE(3y)6.37%
ROCE(5y)5.69%
ROICexcg growth 3Y0.78%
ROICexcg growth 5Y0.88%
ROICexc growth 3Y4.99%
ROICexc growth 5Y3.37%
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
F-Score3
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 1.98
Debt/FCF 20.49
Debt/EBITDA 5.48
Cap/Depr 59.34%
Cap/Sales 2.9%
Interest Coverage 250
Cash Conversion 42.21%
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.73
Altman-Z 0.82
F-Score3
WACC8.28%
ROIC/WACC0.61
Cap/Depr(3y)68.21%
Cap/Depr(5y)61.64%
Cap/Sales(3y)3.1%
Cap/Sales(5y)2.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
EPS Next Y0.71%
EPS Next 2Y17.58%
EPS Next 3Y17.13%
EPS Next 5Y23.05%
Revenue 1Y (TTM)13.54%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%8.17%
Revenue Next Year9.65%
Revenue Next 2Y9.53%
Revenue Next 3Y9.67%
Revenue Next 5Y10.13%
EBIT growth 1Y8.28%
EBIT growth 3Y15.97%
EBIT growth 5Y12.77%
EBIT Next Year47.27%
EBIT Next 3Y22.98%
EBIT Next 5YN/A
FCF growth 1Y159.43%
FCF growth 3Y92.28%
FCF growth 5Y30.27%
OCF growth 1Y72.9%
OCF growth 3Y51.04%
OCF growth 5Y18.3%